Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter Olbrich is active.

Publication


Featured researches published by Peter Olbrich.


Blood | 2017

Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations

Tie Zheng Hou; Nisha Verma; J Wanders; Alan Kennedy; Blagoje Soskic; Daniel Janman; Neil Halliday; Behzad Rowshanravan; Austen Worth; Waseem Qasim; Helen Baxendale; Hans J. Stauss; Suranjith L. Seneviratne; Olaf Neth; Peter Olbrich; Sophie Hambleton; Peter D. Arkwright; Siobhan O. Burns; Lucy S. K. Walker; David M. Sansom

Heterozygous CTLA-4 deficiency has been reported as a monogenic cause of common variable immune deficiency with features of immune dysregulation. Direct mutation in CTLA-4 leads to defective regulatory T-cell (Treg) function associated with impaired ability to control levels of the CTLA-4 ligands, CD80 and CD86. However, additional mutations affecting the CTLA-4 pathway, such as those recently reported for LRBA, indirectly affect CTLA-4 expression, resulting in clinically similar disorders. Robust phenotyping approaches sensitive to defects in the CTLA-4 pathway are therefore required to inform understanding of such immune dysregulation syndromes. Here, we describe assays capable of distinguishing a variety of defects in the CTLA-4 pathway. Assessing total CTLA-4 expression levels was found to be optimal when restricting analysis to the CD45RA-Foxp3+ fraction. CTLA-4 induction following stimulation, and the use of lysosomal-blocking compounds, distinguished CTLA-4 from LRBA mutations. Short-term T-cell stimulation improved the capacity for discriminating the Foxp3+ Treg compartment, clearly revealing Treg expansions in these disorders. Finally, we developed a functionally orientated assay to measure ligand uptake by CTLA-4, which is sensitive to ligand-binding or -trafficking mutations, that would otherwise be difficult to detect and that is appropriate for testing novel mutations in CTLA-4 pathway genes. These approaches are likely to be of value in interpreting the functional significance of mutations in the CTLA-4 pathway identified by gene-sequencing approaches.


Pediatric Allergy and Immunology | 2016

Prospective neonatal screening for severe T‐ and B‐lymphocyte deficiencies in Seville

Beatriz de Felipe; Peter Olbrich; José Manuel Lucenas; Carmen Delgado-Pecellin; Antonio Pavon-Delgado; Josefina Marquez; Carmen Salamanca; Pere Soler-Palacín; Luis Ignacio Gonzalez-Granado; Laura Ferreras Antolin; Stephan Borte; Olaf Neth

Early diagnosis of primary immunodeficiency such as severe combined immunodeficiency (SCID) and X‐linked agammaglobulinemia (XLA) improves outcome of affected children. T‐cell‐receptor‐excision circles (TRECs) and kappa‐deleting‐recombination‐excision circles (KRECs) determination from dried blood spots (DBS) identify neonates with severe T‐ and/or B‐lymphopenia. No prospective data exist of the impact of gestational age (GA) and birth weight (BW) on TRECs and KRECs values.


Anales De Pediatria | 2014

Primer estudio piloto en España sobre el cribado neonatal de las inmunodeficiencias primarias: TRECS y KRECS identifican linfopenias T y B graves

Peter Olbrich; B. de Felipe; Carmen Delgado-Pecellin; R. Rodero; P. Rojas; J. Aguayo; Josefina Marquez; J. Casanovas; Berta Sanchez; J.M. Lucena; Patricia Ybot-Gonzalez; Stephan Borte; Olaf Neth

INTRODUCTION Early diagnosis of primary immunodeficiency such as severe combined immunodeficiency (SCID) and X-linked agammaglobulinemia (XLA) improves outcome of affected infants/children. The measurement of T-cell receptor excision circles (TRECS) and kappa-deleting recombination excision circles (KRECS) can identify neonates with severe T or B-cell lymphopenia. OBJECTIVES To determine TRECS and KRECS levels from prospectively collected dried blood spot samples (DBS) and to correctly identify severe T and B-cell lymphopenia. MATERIAL AND METHODS Determination of TRECS and KRECS by multiplex PCR from neonates born in two tertiary hospitals in Seville between February 2014 and May 2014. PCR cut-off levels: TRECS<15 copies/μl, KRECS<10 copies/μl, ACTB (β-actin)>1000 copies/μl. Internal (XLA, ataxia telangiectasia) and external (SCID) controls were included. RESULTS A total of 1068 out of 1088 neonates (mean GA 39 weeks (38-40) and BW 3238g (2930-3520) were enrolled in the study. Mean (median, min/max) copies/μl, were as follows: TRECS 145 (132, 8/503), KRECS 82 (71, 7/381), and ACTB 2838 (2763, 284/7710). Twenty samples (1.87%) were insufficient. Resampling was needed in one neonate (0.09%), subsequently giving a normal result. When using lower cut-offs (TRECS<8 and KRECS<4 copies/μl), all the samples tested were normal and the internal and external controls were correctly identified. CONCLUSION This is the first prospective pilot study in Spain using TRECS/KRECS/ACTB-assay, describing the experience and applicability of this method to identify severe lymphopenias. The ideal cut-off remains to be established in our population. Quality of sampling, storage and preparation need to be further improved.


Pediatric Allergy and Immunology | 2016

Activated PI3Kδ syndrome type 2: Two patients, a novel mutation and review of the literature

Peter Olbrich; Myriam Ricarda Lorenz; Paola Cura Daball; J.M. Lucena; Anne Rensing-Ehl; Berta Sanchez; Marita Führer; Marisol Camacho-Lovillo; Marta Melon; Klaus Schwarz; Olaf Neth; Carsten Speckmann

Autosomal dominant gain‐of‐function mutations in PIK3R1 encoding for the regulatory subunit (p85α, p55α, and p50α) of Class IA phosphoinositide 3‐kinase (PI3K) result in the activated PI3Kδ syndrome (APDS) type 2 characterized by childhood‐onset combined immunodeficiency, lymphoproliferation, and immune dysregulation. To improve clinical awareness and understanding of these rare diseases, we reviewed all hitherto published cases with APDS type 1 and type 2 for their clinical and immunologic symptoms and added novel clinical, immunologic, and genetic findings of two patients with APDS type 2.


Pediatric Blood & Cancer | 2015

Diagnostic and therapeutic challenges in a child with complete Interferon-γ Receptor 1 deficiency

Peter Olbrich; María Teresa Martínez-Saavedra; José Maria Perez‐Hurtado; Cristina Sánchez; Berta Sanchez; Caroline Deswarte; Ignacio Obando; Jean-Laurent Casanova; Carsten Speckmann; Jacinta Bustamante; Carlos Rodríguez-Gallego; Olaf Neth

Autosomal recessive (AR) complete Interferon‐γ Receptor1 (IFN‐γR1) deficiency is a rare variant of Mendelian susceptibility to mycobacterial disease (MSMD). Although hematopoietic stem cell transplantation (HSCT) remains the only curative treatment, outcomes are heterogeneous; delayed engraftment and/or graft rejection being commonly observed. This case report and literature review expands the knowledge about this rare but potentially fatal pathology, providing details regarding diagnosis, antimicrobial treatment, transplant performance, and outcome that may help to guide physicians caring for patients with AR complete IFN‐γR1 or IFN‐γR2 deficiency. Pediatr Blood Cancer


Frontiers in Immunology | 2018

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry

Maria Elena Maccari; Hassan Abolhassani; Asghar Aghamohammadi; Alessandro Aiuti; Olga Aleinikova; C. Bangs; Safa Barış; Federica Barzaghi; Helen Baxendale; Matthew Buckland; Siobhan O. Burns; Caterina Cancrini; Andrew J. Cant; Pascal Cathébras; Marina Cavazzana; Anita Chandra; Francesca Conti; Tanya Coulter; Lisa A. Devlin; J. David M. Edgar; Saul N. Faust; Alain Fischer; Marina Garcia Prat; Lennart Hammarström; Maximilian Heeg; Stephen Jolles; Elif Karakoc-Aydiner; Gerhard Kindle; Ayca Kiykim; Dinakantha Kumararatne

Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2–3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.


Clinical Infectious Diseases | 2017

Long-Term Impact of an Educational Antimicrobial Stewardship Program on Hospital-Acquired Candidemia and Multidrug-Resistant Bloodstream Infections: A Quasi-Experimental Study of Interrupted Time-Series Analysis

José Molina; Germán Peñalva; María V. Gil-Navarro; Julia Praena; José Antonio Lepe; María Antonia Pérez-Moreno; Carmen Ferrándiz; Teresa Aldabó; Manuela Aguilar; Peter Olbrich; Manuel E. Jiménez-Mejías; María L Gascón; Rosario Amaya-Villar; Olaf Neth; María Jesús Rodríguez-Hernández; Antonio Gutiérrez-Pizarraya; José Garnacho-Montero; Cristina Montero; Josefina Cano; J. Palomino; Raquel Valencia; Rocío Álvarez; Elisa Cordero; Marta Herrero; José Miguel Cisneros; Julián Palomino; Emilio García-Cabrera; Francisco Porras; Francisco Jiménez-Parrilla; Ignacio Obando

Background The global crisis of bacterial resistance urges the scientific community to implement intervention programs in healthcare facilities to promote an appropriate use of antibiotics. However, the clinical benefits or the impact on resistance of these interventions has not been definitively proved. Methods We designed a quasi-experimental intervention study with an interrupted time-series analysis. A multidisciplinary team conducted a multifaceted educational intervention in our tertiary-care hospital over a 5-year period. The main activity of the program consisted of peer-to-peer educational interviews between counselors and prescribers from all departments to reinforce the principles of the proper use of antibiotics. We assessed antibiotic consumption, incidence density of Candida and multidrug-resistant (MDR) bacteria bloodstream infections (BSIs) and their crude death rate per 1000 occupied bed days (OBDs). Results A quick and intense reduction in antibiotic consumption occurred 6 months after the implementation of the intervention (change in level, -216.8 defined daily doses per 1000 OBDs; 95% confidence interval, -347.5 to -86.1), and was sustained during subsequent years (average reduction, -19,9%). In addition, the increasing trend observed in the preintervention period for the incidence density of candidemia and MDR BSI (+0.018 cases per 1000 OBDs per quarter; 95% confidence interval, -.003 to .039) reverted toward a decreasing trend of -0.130 per quarter (change in slope, -0.029; -.051 to -.008), and so did the mortality rate (change in slope, -0.015; -.021 to -.008). Conclusions This education-based antimicrobial stewardship program was effective in decreasing the incidence and mortality rate of hospital-acquired candidemia and MDR BSI through sustained reduction in antibiotic use.


Pediatric Infectious Disease Journal | 2014

Meningoencephalitis due to adenovirus in a healthy infant mimicking severe bacterial sepsis.

Joaquin Reyes-Andrade; Javier Sánchez-Céspedes; Peter Olbrich; Lola Falcon; Inmaculada Sanchez-Ganfornina; Marc Tebruegge; Pilar Pérez-Romero; Olaf Neth

We present the case of a previously healthy 15-month-old girl with acute adenovirus infection who had features of severe bacterial sepsis and meningitis. Real-time qPCR done on cerebrospinal fluid identified adenovirus as the causative agent allowing stopping antibiotic treatment. The patient subsequently recovered without sequelae. An overview of published and unpublished data on adenovirus central nervous system infection in immunocompetent children is presented.


Clinical Immunology | 2018

Study of an extended family with CTLA-4 deficiency suggests a CD28/CTLA-4 independent mechanism responsible for differences in disease manifestations and severity

Tie Zheng Hou; Peter Olbrich; Jose Manuel Lucena Soto; Berta Sanchez; Paula Sanchez Moreno; Stephan Borte; Hans J. Stauss; Siobhan O. Burns; Lucy S. K. Walker; Qiang Pan-Hammarström; Lennart Hammarström; David M. Sansom; Olaf Neth

The CTLA-4 checkpoint regulates the activation of T cells. Individuals with heterozygous mutations in CTLA-4 have a complex phenotype typically characterized by antibody deficiency alongside variable autoimmunity. Despite severe disease in some individuals, others remain largely unaffected with reasons for this variation unknown. We studied a large family carrying a single point mutation in CTLA-4 leading to an amino acid change R75W and compared both unaffected with affected individuals. We measured a variety of features pertaining to T cell and CTLA-4 biology and observed that at the cellular level there was complete penetrance of CTLA-4 mutations. Accordingly, unaffected individuals were indistinguishable from those with disease in terms of level of CTLA-4 expression, percentage of Treg, upregulation of CTLA-4 upon stimulation and proliferation of CD4 T cells. We conclude that the wide variation in disease phenotype is influenced by immune variation outside of CTLA-4 biology.


Immunology and Cell Biology | 2018

CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome

Paola Cura Daball; Mónica S. Ventura Ferreira; Sandra Ammann; Christian Klemann; Myriam Ricarda Lorenz; Ursula Warthorst; Timothy Ronan Leahy; Niall Conlon; Justin Roche; Pere Soler-Palacín; Marina Garcia-Prat; Ilka Fuchs; Sebastian Fuchs; Fabian Beier; Tim H. Brümmendorf; Carsten Speckmann; Peter Olbrich; Olaf Neth; Klaus Schwarz; Stephan Ehl; Anne Rensing-Ehl

Premature T‐cell immunosenescence with CD57+ CD8+ T‐cell accumulation has been linked to immunodeficiency and autoimmunity in primary immunodeficiencies including activated PI3 kinase delta syndrome (APDS). To address whether CD57 marks the typical senescent T‐cell population seen in adult individuals or identifies a distinct population in APDS, we compared CD57+ CD8+ T cells from mostly pediatric APDS patients to those of healthy adults with similarly prominent senescent T cells. CD57+ CD8+ T cells from APDS patients were less differentiated with more CD27+ CD28+ effector memory T cells showing increased PD1 and Eomesodermin expression. In addition, transition of naïve to CD57+ CD8+ T cells was not associated with the characteristic telomere shortening. Nevertheless, they showed the increased interferon‐gamma secretion, enhanced degranulation and reduced in vitro proliferation typical of senescent CD57+ CD8+ T cells. Thus, hyperactive PI3 kinase signaling favors premature accumulation of a CD57+ CD8+ T‐cell population, which shows most functional features of typical senescent T cells, but is different in terms of differentiation and relative telomere shortening. Initial observations indicate that this specific differentiation state may offer the opportunity to revert premature T‐cell immunosenescence and its potential contribution to inflammation and immunodeficiency in APDS.

Collaboration


Dive into the Peter Olbrich's collaboration.

Top Co-Authors

Avatar

Olaf Neth

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stephan Borte

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar

Pere Soler-Palacín

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David M. Sansom

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lennart Hammarström

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar

B. de Felipe

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

Beatriz de Felipe

Spanish National Research Council

View shared research outputs
Researchain Logo
Decentralizing Knowledge